Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

The NetherlandsBack to the Netherlands

Clinical trials in Dordrecht – page 128

1 624 clinical trials in Dordrecht, The Netherlands across 1 research site. Every trial is listed in the EU Clinical Trials Register and updated daily.

The NetherlandsOur site in the NetherlandsKlinischOnderzoek.nl(opens in a new tab)
Dordrecht at a glance
1 624
clinical trials
  • Research sites1
Type of trial
Recruitment status
Quick filters

1 624 trials in Dordrecht

Open in trial search

Non-small cell lung cancer

Not recruiting

Study of Datopotamab Deruxtecan and Pembrolizumab for Patients with Advanced Non-Small Cell Lung Cancer with Low PD-L1 Levels

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Carboplatin
  • Sponsor:Daiichi Sankyo Inc.

Macular oedema

Not recruiting

Study on the Effects of RO7200220 for Adults and Children with Uveitic Macular Edema

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:F. Hoffmann-La Roche AG

Hodgkin's disease

Not recruiting

Study of Tislelizumab, Gemcitabine, and Cisplatin for Patients with Relapsed or Refractory Hodgkin Lymphoma in Metabolic Complete Remission

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cisplatin
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Netherton's syndrome

Not recruiting

Study to Evaluate the Effectiveness of Spesolimab in Treating Patients with Netherton Syndrome

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Spesolimab
  • Sponsor:Boehringer Ingelheim Espana S.A.

High-grade B-cell lymphoma

Not recruiting

Study on the Effect of DA-EPOCH-R and Nivolumab in Patients with Newly Diagnosed High-Grade B-Cell Lymphoma with MYC and BCL2/BCL6 Rearrangements

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
  • Sponsor:Hemato-Oncologie voor Volwassenen Nederland (Hovon) Stichting

Malignant melanoma

Not recruiting

Study on Nivolumab for Preventing Melanoma Recurrence in Patients with Completely Removed Stage IIB/C Melanoma

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

Hidradenitis

Not recruiting

Study on the Effectiveness and Safety of Povorcitinib for Patients with Moderate to Severe Hidradenitis Suppurativa

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Povorcitinib
  • Sponsor:Incyte Corp.

Acute kidney injury

Not recruiting

Study on Ravulizumab for Protecting Chronic Kidney Disease Patients from Acute Kidney Injury After Heart Surgery

Registered drug
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Ravulizumab
  • Sponsor:Alexion Pharmaceuticals Inc.

Neoplasm malignant

Not recruiting

Continued Darolutamide Treatment for Cancer Patients from Previous Bayer Studies

InvestigationalNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Darolutamide
  • Sponsor:Bayer Consumer Care AG

Parkinson's disease

Not recruiting

Study on BIA 28-6156 for Parkinson's Disease in Patients with GBA1 Gene Variant

Investigational
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Sponsor:Bial R&D Investments S.A.

COVID-19+2

Not recruiting

Study on Everolimus and Mycophenolate Mofetil for Improving COVID-19 Vaccine Response in Kidney Transplant Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Everolimus
  • Sponsor:Universitair Medisch Centrum Groningen

Kidney transplant rejection

Not recruiting

Long-Term Follow-Up Study of Imlifidase in Highly Sensitized Kidney Transplant Patients

Registered drugNo placebo
Countries:The NetherlandsThe Netherlands
  • Participants:18–64 years · 65+ years
  • Substances:Imlifidase
  • Sponsor:Hansa Biopharma AB

Other cities in the Netherlands

The busiest research cities in the country

All 101 cities in the Netherlands

Clinical research in Dordrecht

What the registry says about research in the country

01 Hematologic Oncology

Innovative research focusing on Acute Myeloid Leukemia (AML) and various forms of Multiple Myeloma, evaluating novel drug combinations and treatment approaches for patients ineligible for intensive chemotherapy.

  • Blood Cancer Therapies
  • Leukemia Treatment
  • Novel Drug Combinations

Studies aim to improve survival rates and treatment outcomes in previously untreated patients.

02 Cardiovascular Medicine

Research centered on atherosclerotic cardiovascular disease and deep vein thrombosis, investigating new therapeutic approaches and preventive strategies.

  • Heart Disease Management
  • Blood Clot Prevention
  • Cardiac Interventions

Clinical trials focus on improving patient outcomes through innovative treatments and prevention strategies.

03 Endocrine Disorders

Studies examining treatments for thyroid conditions and hormonal disorders, comparing conventional and innovative therapeutic approaches.

  • Thyroid Disease Management
  • Hormone Therapy
  • Quality of Life Improvement

Research aims to enhance treatment efficacy while minimizing side effects.

Back to the NetherlandsAll countries
Clinical Trials Concierge

Prefer not to search on your own, or looking for clinical trials for a rare disease? Our clinical trial advisor will do it for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.